MX2021015770A - Inhibidores macrociclicos de mcl-1. - Google Patents

Inhibidores macrociclicos de mcl-1.

Info

Publication number
MX2021015770A
MX2021015770A MX2021015770A MX2021015770A MX2021015770A MX 2021015770 A MX2021015770 A MX 2021015770A MX 2021015770 A MX2021015770 A MX 2021015770A MX 2021015770 A MX2021015770 A MX 2021015770A MX 2021015770 A MX2021015770 A MX 2021015770A
Authority
MX
Mexico
Prior art keywords
mcl
macrocyclic inhibitors
inhibitors
macrocyclic
useful
Prior art date
Application number
MX2021015770A
Other languages
English (en)
Inventor
Frederik Jan Rita Rombouts
Aldo Peschiulli
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2021015770A publication Critical patent/MX2021015770A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a agentes farmacéuticos útiles para la terapia y/o profilaxis en un sujeto, una composición farmacéutica que comprende tales compuestos y su uso como inhibidores de MCL-1, útiles para tratar o prevenir enfermedades tales como el cáncer. (FORMULA).
MX2021015770A 2019-06-21 2020-06-18 Inhibidores macrociclicos de mcl-1. MX2021015770A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19181605 2019-06-21
PCT/EP2020/066890 WO2020254471A1 (en) 2019-06-21 2020-06-18 Macrocyclic inhibitors of mcl-1

Publications (1)

Publication Number Publication Date
MX2021015770A true MX2021015770A (es) 2022-04-12

Family

ID=67001598

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015770A MX2021015770A (es) 2019-06-21 2020-06-18 Inhibidores macrociclicos de mcl-1.

Country Status (11)

Country Link
US (1) US20220306653A1 (es)
EP (1) EP3986902B1 (es)
JP (1) JP2022537393A (es)
KR (1) KR20220024694A (es)
CN (1) CN114641481A (es)
AU (1) AU2020296918A1 (es)
BR (1) BR112021025732A2 (es)
CA (1) CA3143613A1 (es)
MA (1) MA56505A (es)
MX (1) MX2021015770A (es)
WO (1) WO2020254471A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019347963A1 (en) * 2018-09-30 2021-05-27 Jiangsu Hengrui Medicine Co., Ltd. Indole macrocyclic derivative, preparation method therefor and application thereof in medicine
WO2020103864A1 (en) * 2018-11-22 2020-05-28 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic indoles as mcl-1 inhibitors
EP4107161A1 (en) * 2020-02-21 2022-12-28 Janssen Pharmaceutica NV Macrocyclic indole derivatives as inhibitors of mcl-1
CA3206202A1 (en) * 2021-02-12 2022-08-18 Janssen Pharmaceutica Nv Macrocyclic 1,3-bridged 6-chloro-7-pyrazol-4-yl-1h-indole-2-carboxylate and 6-chloro-7-pyrimidin-5-yl-1h-indole-2-carboxylate derivatives as mcl-1 inhibitors for the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202000191YA (en) * 2014-01-24 2020-03-30 Turning Point Therapeutics Inc Diaryl macrocycles as modulators of protein kinases
JO3474B1 (ar) * 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
WO2017182625A1 (en) 2016-04-22 2017-10-26 Astrazeneca Ab Macrocyclic mcl1 inhibitors for treating cancer
TW201904976A (zh) 2017-03-31 2019-02-01 瑞典商阿斯特捷利康公司 Ｍｃｌ-１抑制劑及其使用方法
TWI781996B (zh) 2017-03-31 2022-11-01 瑞典商阿斯特捷利康公司 合成ｍｃｌ-１抑制劑之方法
UY37844A (es) * 2017-08-15 2019-03-29 Abbvie Inc Inhibidores de mcl-1 macrocíclicos y métodos de uso
AU2019347963A1 (en) 2018-09-30 2021-05-27 Jiangsu Hengrui Medicine Co., Ltd. Indole macrocyclic derivative, preparation method therefor and application thereof in medicine
WO2020103864A1 (en) 2018-11-22 2020-05-28 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic indoles as mcl-1 inhibitors

Also Published As

Publication number Publication date
WO2020254471A1 (en) 2020-12-24
US20220306653A1 (en) 2022-09-29
AU2020296918A1 (en) 2022-02-17
JP2022537393A (ja) 2022-08-25
KR20220024694A (ko) 2022-03-03
EP3986902B1 (en) 2024-01-24
BR112021025732A2 (pt) 2022-04-12
CN114641481A (zh) 2022-06-17
EP3986902A1 (en) 2022-04-27
MA56505A (fr) 2022-04-27
CA3143613A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MY194586A (en) Anti-garp antibody
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2023002507A (es) Inhibidores de cd73.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
MX2022015813A (es) 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
MX2017005284A (es) Nuevos derivados de pirazolopirimidina de la cinasa inductora de nf-kb (nk).
PH12016502352A1 (en) Pharmaceutical composition
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
NZ788133A (en) Cd73 inhibitors
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
PH12020500666A1 (en) Pladienolide compounds and their use
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
MX2022006180A (es) Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.
MX2022006179A (es) Derivados macrociclicos de indol como inhibidores de mcl-1.
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
MX2022016179A (es) Compuestos y metodos para tratar infecciones fungicas.
MX2022015005A (es) Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1.
MX2021015898A (es) Compuestos heterocíclicos bicíclicos como inhibidores de actividad de ofbcdin3d.
MX2020013805A (es) Derivados de piridopirimidinona para uso como inhibidores de axl.
MX2022010299A (es) Derivados macrocíclicos de indol como inhibidores de mcl-1.